Search Articles — Sudonull

Search Results

From other projects

Telitacicept in IgA Nephropathy: Phase 3 Results in NEJM

https://ymaho.com/telitacicept-in-iga-nephropathy-phase-3-results-in-nejm

Interim Results of TELIGAN: Telitacicept Reduces Proteinuria by 58.9% vs 8.8% Placebo. Learn How the New Dual Inhibitor Is Changing the IgA Nephropathy Market.

CRISPR therapy in vivo: Intellia study 87% efficacy in HAE

https://ymaho.com/crispr-therapy-in-vivo-intellia-study-87-efficacy-in-hae

Phase 3 HAELO: single CRISPR infusion reduced hereditary angioedema attacks by 87% vs placebo. First in vivo therapy on the verge of registration. Details, insights, forecasts.

Trending Now